Board of Directors

Robbie Melton is the Program Manager for Entrepreneurial Development at the Maryland Technology Development Corporation (TEDCO).  Robbie works directly with technology start up companies to determine the viability and worthiness of the firm for candidacy for TEDCO funding programs and assists companies with other investment opportunities and business needs. She serves on review committees for a number of state funded technology programs and is a director of the MIT Enterprise Forum Board. Robbie has nearly 20 years experience in managing technology development and commercialization projects in a broad range of technologies. For five years she was the operations manager for the Center for Cancer and Transplantation Biology at the Children's National Medical Center.  Robbie holds a Master's degree in Science, Technology and Public Policy from The George Washington University.

Cynthia Wong Hu is Vice President, General Counsel and Secretary of EntreMed, Inc. She is primarily responsible for managing all aspects of EntreMed's legal activities, including transactions and compliance, management of our external legal services, and interactions with EntreMed's Board. Ms. Hu has also been appointed by the Board as Secretary and as an executive officer of the Company. Prior to joining EntreMed, she served as a senior attorney for the business finance practice group at Powell Goldstein LLP, in Washington, DC., where she advised clients with regard to public and private financing transactions, partnership and operating agreements, various corporate agreements, mergers and acquisitions, SEC compliance matters, stock and asset purchase agreements and general corporate matters. Before that, Ms. Hu served as internal counsel for Golden American Life Insurance Company focusing on filings and compliance with the Securities Act of 1933 and the Investment Company Act of 1940. She is also a Director of Strathmore Hall Foundation, Inc. Ms. Hu received her J.D. from Rutgers University School of Law in 1994 and is admitted to the Bar in New York , Pennsylvania and the District of Columbia .

Phyllis Dillinger is the Executive Vice President and C.F.O. of KPL.  KPL manufactures and distributes antibodies and reagents to the Life Science Research community.  During her 11 years with KPL, Ms. Dillinger completed a divestiture, spun off a separate Genomics business and most recently relocated the organization to a 30,000 square foot state of the art facility.  Prior to joining KPL, she was C.F.O. of Sopha Medical the French held U.S. subsidiary manufacturing gamma cameras for 10 years.  During her stay at Sopha, sales grew from $1M to $42M. She completed a $85M dollar merger between Sopha Medical and Summit Vision and relocated the new organization to Cleveland , Ohio . Ms. Dillinger holds an M.B.A. from The George Washington University

Sue Hendrickson is a Partner in the Intellectual Property and Technology Practice Group of Arnold & Porter LLP.  Her practice focuses on technology-related transactions and the protection, development, transfer and commercialization of intellectual property assets.  Ms. Hendrickson routinely represents pharmaceutical, biotech, medical device and other life sciences companies in connection with their commercial arrangements.  She has advised on life sciences transactions involving all phases of the product life cycle, from early research, development and financing efforts, through clinical trials, product approval, manufacturing, marketing and commercialization and next generation product development.  Among other matters, she has represented pharmaceutical and other life sciences companies in connection with licensing transactions, research and development agreements, clinical trial agreements, co-promotion and co-marketing agreements, feasibility and proof of concept studies, distribution agreements, manufacturing and supply arrangements, strategic alliances, product acquisitions and divestitures and other commercial arrangements.

Shira Kramer, Ph.D., is the President and a Founder of the Sterilex Corporation.  She holds a Ph.D. in Epidemiology, a Masters degree in Human Genetics, and a Bachelors degree in Biochemistry, all from The Johns Hopkins University. Dr. Kramer formed the Sterilex Corporation in 1995, with the goal of developing and marketing novel antimicrobial products that are designed to overcome the factors responsible for antimicrobial resistance.  Sterilex current technology platform targets bacterial biofilm, and the companys patented products are used in health and dental care, food processing, water treatment, and industrial applications.  Sterilex is the proud recipient of the Technology Council of Maryland 2004 Bio Product of the Year Award. Prior to  her activities at Sterilex, Dr. Kramer, in 1984, founded RidgeCom, Inc., an epidemiological research and consulting firm.  At RidgeCom, Dr. Kramer conducted a wide variety of epidemiological studies for industry (petroleum, chemical, and pharmaceutical companies);  academic institutions;  and governmental agencies. From 1978-1985, Dr. Kramer served as a member of the faculty at the University of Pennsylvania School of Medicine, and directed an epidemiological research program to identify risk factors for childhood cancers at the Childrens Hospital of Philadelphia.  During that time, she published numerous articles on the epidemiology and etiology of childhood cancers, published two textbooks on epidemiologic methods, and taught graduate-level courses in epidemiology.

Susan Mack is a senior partner at the intellectual property law firm of Sughrue Mion, PLLC., where she is a member of the chemical, the biotechnology and pharmaceutical, the nanotechnology, and the interference groups.  Susan counsels clients in all aspects of patent practice. She lectures in a variety of areas, including chemical and pharmaceutical patent practice,  the laws pertaining to generic and brand name drugs, and nanotechnology patent practice. She holds a masters degree in biophysics and genetics from the University of Colorado Health Science Center and a juris doctorate from The American University, Washington college of Law.

Carol Nacy, Ph.D. was Executive Vice President and CSO at EntreMed, Inc. from 1993 through its successful public offering in June 1996.  She left EntreMed in November 1996 to establish Sequella, Inc. and was part-time CSO (1997-98) for Anergen, Inc., a California company focused on autoimmune diseases. There, she reorganized the scientific staff and approach and positioned the company for acquisition by Corixa Corp. in December 1998.  Dr. Nacy became a full-time CEO and Chair of Sequella and began drawing salary in January 1999.  She is a member of the Board of Directors of several companies(ASMResources, TolerGenics, Social and Scientific Systems) and non-profit agencies (Sequella Foundation, Women in BIO).  Before her business experience, she was a Career Scientist and Science Manager at the Walter Reed Army Institute of Research and the National Institutes of Health for seventeen years.